Driving Progress in MCS: magAssist Highlights at ASAIO 2025

At the 2025 ASAIO Annual Meeting in New Orleans, magAssist shared its latest developments in mechanical circulatory support (MCS) through invited talks, abstract presentations, and posters. The team highlighted innovations in short- and mid-term cardiac support and exchanged insights with international experts.

Industry Updates: Presenting Key Technologies in MCS

In the high-profile Industry Updates session—moderated by Dr. Bud Frazier, Dr. Kurt Dasse, and Dr. Jamshid Karimov—magAssist was invited to introduce the company's three core product platforms:

• NyokAssist®: A minimally invasive, foldable short-term ventricular assist device (VAD), designed to enhance patient mobility and streamline procedural access in acute cardiac failure.

• MoyoAssist®: A magnetically levitated extracorporeal VAD offering stable support for short- to mid-term indications. The system emphasizes hemodynamic performance and user-friendly operation in clinical settings.

• Next-generation modular life support platform (in development): A flexible system architecture targeting future multi-organ and multi-scenario applications, aimed at improving adaptability across complex clinical needs.

Prof. Po-Lin Hsu, Founder and CEO of magAssist, joined senior leaders from the industry—including the Chief Medical Officer of Abbott—in a forward-looking dialogue on the future of MCS innovation.

Research Recognition: ASAIO Abstract Award

Thomas Logan, a magAssist research team member, received an ASAIO Abstract Award for his study titled "Percutaneous Transvalvular Ventricular Assist Device Performance in High-Risk Percutaneous Coronary Intervention". The research focused on hemodynamic support strategies during high-risk percutaneous coronary interventions, aligning closely with NyokAssist®'s intended use. This recognition reflects the company's ongoing efforts to bridge engineering with clinical validation.

Academic Contributions Across Clinical and Engineering Topics

magAssist contributed five oral presentations and four posters across multiple sessions, spanning clinical application, device optimization, and computational modeling.

Clinical and Bioengineering

• In the Cardiac Clinical 1 session, the team shared multicenter data on an extracorporeal centrifugal flow pump for temporary cardiac support, offering insights into real-world clinical pathways.

• In Bioengineering 1, a lumped-parameter simulation study examined VAD function in patients with ventricular septal defects, supporting the design of personalised patient treatment strategies.

High-Risk PCI and Component Optimization

• In Cardiogenic Shock 3, the team detailed the hemodynamic effects of transvalvular VADs in high-risk PCI cases, providing reference data for procedural planning.

• Another presentation from the team proposed a method for oxygenator flow field optimization using CFD modeling, aiming to reduce low-flow, low-oxygenation regions and enhance device efficiency.

• Four posters, including “Advances in Innovative Magnetically Levitated Blood Pump Development,” demonstrated magAssist's technical progress in pump fluid dynamics and biocompatible material applications, bridging basic research and clinical needs.

Recognition from MCS Experts

Two leading experts at ASAIO 2025 acknowledged magAssist's technological advancements：

• Dr. Richard Wampler, known as the “Father of Rotary Blood Pumps,” acknowledged the clinical potential of NyokAssist®.

• Dr. Kurt Dasse, co-developer of CentriMag, affirmed the technical strength of MoyoAssist® ExtraVAD.

• Both experts were honored with ASAIO's Lifetime Achievement Award, underscoring their continued contributions to the MCS community. 

The recognition received at ASAIO 2025—from scientific peers and veteran leaders alike—affirms past efforts while motivating future advancements.

In the MCS field, even small steps forward can offer significant hope for patients and meaningful progress for the industry.

About ASAIO

ASAIO (formerly known as the American Society for Artificial Internal Organs) fosters cross-disciplinary collaboration to advance medical device technologies at the intersection of engineering, medicine, and science. With over six decades of history, ASAIO remains a central platform for sharing innovations in artificial organs, regenerative medicine, and mechanical support systems.